Astellas Pharma Inc.
Astellas Pharma Inc. is a Japanese public company registered in Japan under corporate number 5010001034966, as recorded on the National Tax Agency’s Corporate Number Publication Site (Houjin Bangou). That number was assigned nationwide on 5 October 2015, when Japan introduced its My Number corporate-numbering system and issued 13-digit corporate numbers to all existing registered entities; this date reflects that nationwide registry rollout rather than Astellas Pharma Inc.’s own founding date. Astellas Pharma Inc. was actually established on 1 April 2005, through the merger of two long-established Japanese pharmaceutical companies, Yamanouchi Pharmaceutical Co., Ltd. (founded 1923) and Fujisawa Pharmaceutical Co., Ltd. (founded 1894). Its registered head office is at 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, and its registry status is recorded as active.
Astellas Pharma Inc. is a research-based pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. According to the company’s own corporate materials, its current portfolio and pipeline are organised around five priority disease areas – oncology, ophthalmology, urology, immunology and women’s health – building on legacies in urological medicine and chemical synthesis inherited from Yamanouchi and in transplant immunology and fermentation technology inherited from Fujisawa. The company reports operations in more than 70 countries and areas and states that its medicines have reached more than 172 million patients in 103 countries and areas since its formation.
Astellas Pharma Inc.’s shares are listed on the Tokyo Stock Exchange under securities code 4503, and the company is a constituent of both the TOPIX Core 30 and Nikkei 225 indices. For the financial year ended 31 March 2026 (FY2025), Astellas Pharma Inc. reported group revenue of approximately ¥2,139.2 billion (around $14.17 billion), with research and development spending equivalent to 14.7% of sales revenue, according to the company’s own investor disclosures. Astellas Pharma Inc. reported more than 14,000 employees worldwide as of its most recently published corporate profile.
April 2025 marked the company’s 20th anniversary since the 2005 merger. Recent developments described in the company’s own materials include the acquisitions of the biopharmaceutical companies Iveric Bio and Propella Therapeutics, the establishment of research hubs including TME iLab and SakuLab-Tsukuba, and continued expansion of its United States research and commercial footprint, including facilities described as West Coast and Cambridge Life Sciences Centers.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
1
Shareholders of Astellas Pharma Inc.
Astellas Pharma Inc. is listed on the Tokyo Stock Exchange, and its investor relations disclosure publishes only its principal shareholders rather than a complete shareholder register. According to that disclosure, dated 31 March 2026, Astellas Pharma Inc. had 1,809,663,075 shares of common stock issued and 401,165 shareholders of record. The largest disclosed holder was Master Trust Bank of Japan, Ltd. (trust account), with 343,200 thousand shares equal to 18.96% of shares outstanding, followed by Custody Bank of Japan, Ltd. (trust account) with 7.19%. Both are Japanese trust banks holding shares in a trust-account capacity on behalf of multiple underlying institutional clients, rather than as beneficial owners in their own right. Other disclosed holders included Nippon Life Insurance Company (2.85%), State Street Bank and Trust Company 505001 (2.12%), two separate JPMorgan Securities Japan Co., Ltd. holdings (1.66% and 1.22%), JPMorgan Chase Bank 385781 (1.46%), SMBC Nikko Securities Inc. (1.24%), Nomura Trust and Banking Co., Ltd. (Investment Trust Account) (1.18%), and a further Custody Bank of Japan, Ltd. trust account (1.04%). No single shareholder or identifiable group held a majority stake, and the two leading trust-bank accounts together represented approximately 26.15% of shares outstanding.
Ultimate beneficial ownership
No individual ultimate beneficial owner is identified in Astellas Pharma Inc.’s shareholder disclosure. The largest holdings are recorded in the names of trust banks and custodian accounts acting for numerous underlying institutional and investment-fund clients whose individual identities and holdings are not broken out in the disclosure reviewed, so no natural person’s effective ownership percentage can be reliably calculated from the sources available for this profile.
Data availability
Classification: Major shareholders only. Astellas Pharma Inc. publishes its principal shareholders as part of its periodic investor relations disclosure, consistent with Japanese listed-company practice, but does not publish a complete shareholder register or the identities of the underlying clients of its trust-account and nominee holders.
Sources
- Astellas Pharma Inc. – investor relations stock and shareholder disclosure, dated 31 March 2026
Registry feed — rows exactly as filed with National Tax Agency — Corporate Number Publication Site, including entries the profile above does not cover.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Nbc Securities, Inc. | 14.7% | National Tax Agency — Corporate Number Publication Site |
Officers
15
Directors and officers of Astellas Pharma Inc.
Astellas Pharma Inc.’s corporate website lists ten members of its Board of Directors as of July 2026. The board is chaired by Kenji Yasukawa, Representative Director and Chairman of the Board, appointed April 2023. Naoki Okamura serves as Representative Director, President and Chief Executive Officer, also appointed April 2023, and Katsuyoshi Sugita serves as Representative Director, Executive Vice President and Chief People Officer, appointed June 2023. The board also includes outside directors Masahiro Miyazaki and Yoichi Ohno (appointed June 2023) and Mark Enyedy (appointed June 2025), together with Audit & Supervisory Committee members Rika Hirota (appointed June 2024), Rie Akiyama (appointed June 2023), Tomoko Aramaki (appointed June 2024) and Shigeki Takahara (appointed June 2026). Below board level, the company’s published executive management team includes Tadaaki Taniguchi as Chief Research & Development Officer, Rao Mantri as Chief Manufacturing Officer, Claus Zieler as Chief Commercial & Medical Affairs Officer, Takahiko Iwaya as Chief Strategy Officer, Atsushi Kitamura as Chief Financial Officer, and Tatjana Dragovic as General Counsel and Chief Ethics & Compliance Officer. Nationality and country of residence are not disclosed for any board member or executive officer in the sources reviewed for this profile.
Recent officer changes
Shigeki Takahara was appointed Outside Director, Audit & Supervisory Committee Member, in June 2026, the most recent board appointment reflected in the sources reviewed. Mark Enyedy joined the board as an Outside Director in June 2025. Rao Mantri joined the company as Chief Manufacturing Officer in February 2025.
Data availability
Classification: Current only. This overview reflects the board and executive management composition published on Astellas Pharma Inc.’s corporate website as of July 2026; it does not include a full history of prior resignations, and the company’s public disclosures reviewed for this profile do not state directors’ or officers’ nationality or country of residence.
Sources
- Astellas Pharma Inc. – corporate leadership / board of directors and executive management page, as of July 2026
Registry feed — rows exactly as filed with National Tax Agency — Corporate Number Publication Site, including entries the profile above does not cover.
Group Structure
Group structure of Astellas Pharma Inc.
Astellas Pharma Inc. is the Tokyo Stock Exchange-listed parent and financial-reporting entity for its worldwide operations; the sources reviewed for this profile do not identify it as a subsidiary of any other operating corporate group. The company’s own materials state that it operates in more than 70 countries and areas but do not publish a complete, itemised list of subsidiary legal entities with ownership percentages on its public corporate website. Registry-sourced corporate-linkage data reviewed for this profile lists additional group entities, including Astellas B.V. (Netherlands, registration number NL 33193274) and Astellas Pharma Capability Centre India Private Limited (India, registration number U62099KA2025FTC198796); these relationships were not independently re-verified against an official Astellas filing for this profile and are presented below as possible rather than confirmed. Information is current as of September 2026.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Astellas B.V. | Netherlands | NL 33193274 | Possible subsidiary (reported in registry-sourced group data; not independently re-verified for this profile) | Ownership percentage not disclosed | Active | September 2026 |
| Astellas Pharma Capability Centre India Private Limited | India | U62099KA2025FTC198796 | Possible subsidiary (reported in registry-sourced group data; not independently re-verified for this profile) | Ownership percentage not disclosed | Active | September 2026 |
Data availability
Classification: Partial. Astellas Pharma Inc. confirms a large multinational operating footprint in its own materials, but a complete, ownership-percentage-verified subsidiary registry was not found on its public corporate website during this review; the entities listed above come from registry-sourced group data that has not been independently re-verified here.
Sources
- Astellas Pharma Inc. – corporate/about pages describing global operations, September 2026
- Registry-aggregated corporate-linkage data compiled for this company profile
Astellas Pharma Inc.
Japan
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What is Astellas Pharma Inc.?
Astellas Pharma Inc. is a Japanese research-based pharmaceutical company headquartered in Tokyo and listed on the Tokyo Stock Exchange under ticker 4503. It discovers, develops, manufactures and markets prescription medicines, with its current portfolio and pipeline organised around oncology, ophthalmology, urology, immunology and women's health.
When was Astellas Pharma Inc. founded?
Astellas Pharma Inc. was established on 1 April 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. (founded 1923) and Fujisawa Pharmaceutical Co., Ltd. (founded 1894).
Does the "2015-10-05" date shown on Astellas Pharma Inc.'s registry record mean the company was founded in 2015?
No. That date reflects when Japan's National Tax Agency assigned and published a 13-digit corporate number (Houjin Bangou) for Astellas Pharma Inc. under the nationwide My Number corporate-numbering system introduced on 5 October 2015 for all pre-existing registered entities in Japan. It is not Astellas Pharma Inc.'s incorporation or founding date; the company was actually founded on 1 April 2005.
What is Astellas Pharma Inc.'s corporate registration number?
Astellas Pharma Inc.'s Japanese corporate number (Houjin Bangou) is 5010001034966, as recorded on the National Tax Agency's Corporate Number Publication Site.
Where is Astellas Pharma Inc. headquartered?
Astellas Pharma Inc.'s registered head office is at 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan.
On which stock exchange is Astellas Pharma Inc. listed?
Astellas Pharma Inc. shares trade on the Tokyo Stock Exchange under securities code 4503, and the company is a constituent of the TOPIX Core 30 and Nikkei 225 indices.
What are Astellas Pharma Inc.'s main therapeutic areas?
Astellas Pharma Inc.'s current portfolio and pipeline are organised around five priority disease areas: oncology, ophthalmology, urology, immunology and women's health.
How much revenue did Astellas Pharma Inc. report for its most recent financial year?
For the financial year ended 31 March 2026 (FY2025), Astellas Pharma Inc. reported group revenue of approximately ¥2,139.2 billion (around $14.17 billion), according to its own investor disclosures.
Who is the CEO of Astellas Pharma Inc.?
Naoki Okamura serves as Representative Director, President and Chief Executive Officer of Astellas Pharma Inc., a position he has held since April 2023.
Who chairs Astellas Pharma Inc.'s board of directors?
Kenji Yasukawa serves as Representative Director and Chairman of the Board of Astellas Pharma Inc., appointed in April 2023.
Who are Astellas Pharma Inc.'s major shareholders?
As of 31 March 2026, Astellas Pharma Inc.'s largest disclosed shareholders were Master Trust Bank of Japan, Ltd. (trust account), holding 18.96% of shares outstanding, and Custody Bank of Japan, Ltd. (trust account), holding 7.19%. Both hold shares in a trust-account capacity for multiple underlying institutional clients rather than as ultimate beneficial owners.
Does Astellas Pharma Inc. have an identified ultimate beneficial owner?
No natural-person ultimate beneficial owner is identified in Astellas Pharma Inc.'s shareholder disclosure. Its largest holdings are recorded under trust-bank and custodian accounts acting for numerous underlying clients whose individual identities are not itemised in the sources reviewed.
Is Astellas Pharma Inc. a subsidiary of another company?
No. Astellas Pharma Inc. is the Tokyo Stock Exchange-listed parent and financial-reporting entity for its worldwide group. The sources reviewed for this profile do not identify it as a subsidiary of another operating corporate group.
How did Astellas Pharma Inc. get its name?
The name "Astellas" combines Latin, Greek and English words relating to "stars," reflecting the concept of "aspired stars." It was adopted following the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.